Bookmark

Add to MyYahoo RSS

Crucell NV News

News on Crucell NV (Ticker: JNJ) continually updated from thousands of sources around the net.

May 28, 2013 | PR-inside.com

Market Report, "Crucell N.V. - Strategic SWOT Analysis Review", published

Crucell N.V. is a biopharmaceutical company. It discovers, develops, manufactures and markets vaccines and antibodies indicated against infectious diseases.

Comment?

Related Topix: Crucell NV, Biotech, Medicine, Healthcare Industry, Infectious Diseases

Fri Nov 30, 2012

NorthJersey.com

Johnson & Johnson chief Gorsky elected to chairman of the board

Weldon will step down as chairman on Dec. 28 and plans to retire in the first quarter of 2013, the New Brunswick-based company said in a statement today.

Comment?

Related Topix: Biotech, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Advanced Transit Dynamics, DePuy Orthopaedics, Pinnacle Health System, Medical Equipment, Hospital Administration, St Peters Health Care Services

Mon Nov 12, 2012

PR-inside.com

Crucell N.V. - SWOT, Strategy and Corporate Finance Report - new company profile report published

The report covers the companys structure, operation, SWOT analysis, product and service offerings, detailed financials, and corporate actions, providing a 360E s view of the company.

Comment?

Related Topix: Biotech, Healthcare Industry

Mon Oct 22, 2012

PR-inside.com

Crucell N.V. a " Mergers & Acquisitions (M&A), Partnerships &...

Crucell N.V. A A A' Mergers & Acquisitions , Partnerships & Alliances and Investment Report - new company profile report published 2012-10-22 14:11:50 - Crucell N.V. A A A' Mergers & Acquisitions , Partnerships & Alliances and Investment Report - a new company profile report on companiesandmarkets.com The Company Mergers & Acquisitions , ... (more)

Comment?

Related Topix: Crucell NV, Biotech, Medicine, Healthcare Industry

Mon Oct 08, 2012

BioSpace

Mucosis B.V. Signs Research and License Option Agreement With Crucell N.V.

Mucosis BV, a clinical-stage Dutch biotechnology company developing innovative mucosal vaccines, today announced that it has signed a Research and License Option Agreement with Crucell Holland B.V. , the Dutch developer of vaccines and antibodies.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Johnson & Johnson, Johnson and Johnson, Johnson and Johnson Merck Consumer Pharmaceuticals, Infectious Diseases, Vaccinations, Health

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••
•••